New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
10:07 EDTOSIS, ROP, MYL, GME, RF, GMCR, SDRL, GPSOn The Fly: Analysts Upgrade Summary
Today's noteworthy upgrades include: Gap (GPS) upgraded to Hold from Sell at Canaccord...Regions Financial (RF) upgraded to Outperform from Neutral at RW Baird...Roper Industries (ROP) upgraded to Buy from Neutral at Citigroup...Seadrill (SDRL) upgraded to Outperform from Neutral at Credit Suisse...GameStop (GME) upgraded to Buy from Above Average at Caris...OSI Systems (OSIS) upgraded to Outperform from Perform at Oppenheimer...Green Mountain (GMCR) upgraded to Buy from Neutral at Dougherty...Mylan (MYL) upgraded to Outperform from Market Perform at Leerink.
News For GPS;RF;ROP;SDRL;GME;OSIS;GMCR;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 11, 2014
09:00 EDTGMCRKeurig Green Mountain announces expanded agreement with Caribou Coffee
Subscribe for More Information
07:32 EDTMYLMylan launches generic version of Hikma Maple's Robaxin injection
Subscribe for More Information
07:06 EDTMYLMylan launches generic version of Orapred ODT
Mylan announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT. Mylan received final approval from the FDA for its Abbreviated New Drug Application for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg, and was awarded 180 days of generic drug marketing exclusivity. This product is indicated as an anti-inflammatory or immunosuppressive agent for certain conditions; and also for the treatment of certain endocrine conditions, and for palliation of certain neoplastic conditions. Prednisolone Sodium Phosphate Orally Disintegrating Tablets had U.S. sales of approximately $19.9M for the 12 months ending September 30.
December 10, 2014
11:41 EDTGMCRGreen Mountain Coffee December calls active
Green Mountain Coffee December weekly 140 calls are active on total call volume of 2,200 contracts, compared to its open interest of 395 contracts. December weekly call option implied volatility is at 57, December is at 37, January is at 32, March is at 33; compared to its 26-week average of 42 according to Track Data. Active call volume suggests traders taking positions for large near term price movement
09:36 EDTSDRLActive equity options trading
Subscribe for More Information
07:38 EDTMYLMylan launches generic version of Pfizer's Celebrex capsules
Mylan (MYL) announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's (PFE) Celebrex Capsules, indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. Celecoxib Capsules had U.S. sales of approximately $2.5B for the 12 months ending September 30, 2014.
December 8, 2014
11:30 EDTMYLLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
December 5, 2014
18:01 EDTGPSGap shares look cheap, should continue to rise, Barron's reports
Subscribe for More Information
10:59 EDTSDRLStocks with call strike movement; SDRL GPRO
Subscribe for More Information
10:05 EDTMYLBristol-Myers jumps 2% amid talk of potential Pfizer bid
Shares of Bristol-Myers (BMY) are up in early trading amid chatter of a potential takeover bid from Pfizer (PFE). The stock is up $1.26 to $60.15. Bristol's market capitalization stands around $99B, less than twice that of Pfizer's $200B. A Jefferies analyst last week called Mylan (MYL) the most likely takeover target for Pfizer. Pfizer is "highly motivated" to buy a foreign company using its overseas cash and Mylan looks like the most likely target, Jefferies analyst Jeffrey Holford wrote.
09:17 EDTGPSOn The Fly: Pre-market Movers
Subscribe for More Information
December 4, 2014
18:34 EDTGPSOn The Fly: After Hours Movers
Subscribe for More Information
16:30 EDTGPSGap up approximately 4% following November sales results
Subscribe for More Information
16:06 EDTGPSGap reports November SSS up 6%
Subscribe for More Information
16:02 EDTGMCRKeurig Green Mountain to acquire Bevyz Global for $220M
Keurig Green Mountain announced that it has entered into an agreement to acquire the outstanding equity of MDS Global Holding p.l.c. that it does not already own. The transaction is valued at approximately $220M in cash, based on exchange rates as of the close of business on December 3. Keurig currently owns approximately 15% of Bevyz on a fully diluted basis and will fund the acquisition with cash on hand. The transaction is subject to customary closing conditions and is expected to close in the next month. Following the acquisition, Bevyzís roughly 50 employees will become part of Keurigís technology and product systems teams and are expected to continue to be located primarily in the Netherlands and Malta. Keurig reiterated its FY15 and Q1 guidance provided in its November 19, earnings press release.
16:02 EDTGPSGap reports November SSS up 6%
Subscribe for More Information
16:01 EDTGPSGap reports November sales $1.72B, up 6%
Subscribe for More Information
16:01 EDTGMCRKeurig Green Mountain to acquire Bevyz Global for $220M
10:03 EDTMYLMylan receives tentative FDA approval for abacavir/lamivudine NDAs
Mylan announced that its subsidiary Mylan Laboratories has received tentative approval from the FDA for its New Drug Applications for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients. This is the first version of abacavir/lamivudine with scoring to allow for dose adjustment and is also flavored, Mylan said. The FDA's tentative approval through the President's Emergency Plan for AIDS Relief program means the formulations meet all of the agency's quality, safety and efficacy standards, it stated. The tentative approval follows a 2012 agreement between Mylan, Clinton Health Access Initiative and ViiV Healthcare to transfer the necessary technology and resources to facilitate regulatory authority submission, production and distribution of the new formulation to a total of 115 resource limited countries including all low-middle income, least developed countries and sub-Saharan Africa. Mylan's products are expected to be eligible for purchase in early 2015.
08:37 EDTGMCRKeurig Green Mountain acquires Laughing Man Coffee and Tea brand
Keurig Green Mountain announced it has acquired the Laughing Man Coffee and Tea brand from Laughing Man Worldwide. Keurig will introduce Laughing Manís curated selection of gourmet coffees and teas to Keurig brand packs for use in Keurig brewers beginning in spring 2015. Financial terms of the agreement were not disclosed.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use